Cipher Pharmaceuticals (TSE:CPH) Stock Price Breaks Below 50 Day Moving Average – Here’s Why

Posted by Alanna Baker on Oct 9th, 2026

Shares of Cipher Pharmaceuticals Inc. (TSE:CPH – Get Free Report) (NASDAQ:CPHR) passed below its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of C$14.71 and traded as low as C$13.66. Cipher Pharmaceuticals shares last traded at C$13.66, with a volume of 11,032 shares traded.

Cipher Pharmaceuticals Price Performance

The company has a market capitalization of C$346.91 million, a PE ratio of 12.19 and a beta of 1.26. The company’s 50 day moving average is C$14.65 and its two-hundred day moving average is C$16.34. The company has a quick ratio of 2.67, a current ratio of 1.59 and a debt-to-equity ratio of 0.27.

Cipher Pharmaceuticals (TSE:CPH – Get Free Report) (NASDAQ:CPHR) last announced its quarterly earnings results on Tuesday, August 11th. The company reported C$0.21 EPS for the quarter. Cipher Pharmaceuticals had a net margin of 58.81% and a return on equity of 22.74%. The business had revenue of C$17.14 million for the quarter. On average, analysts anticipate that Cipher Pharmaceuticals Inc. will post 1.29 earnings per share for the current year.

Insider Activity at Cipher Pharmaceuticals

In other news, Director Craig Mull bought 20,000 shares of the firm’s stock in a transaction that occurred on Friday, September 18th. The shares were bought at an average cost of C$14.16 per share, for a total transaction of C$283,200.00. Following the completion of the transaction, the director owned 1,009,953 shares of the company’s stock, valued at approximately C$14,300,934.48. This represents a 2.02% increase in their ownership of the stock. Corporate insiders own 42.00% of the company’s stock.

About Cipher Pharmaceuticals

(Get Free Report)

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.